Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis. This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL17 inhibitor or an IL23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).
Study Type
OBSERVATIONAL
Enrollment
66
52 weeks
52 weeks
52 weeks
Andreas Sygros Hospital
Athens, Greece
change of pulse wave velocity (PWV) from baseline to week 24 and 52
PWV can range from approximately 6.6 m/s in patients under 30 to 11.7 m/s in patients over 70 years of age; higher scores mean a worse outcome
Time frame: from enrollment to the end of treatment at week 52
change of augmentation index normalized to 75 beats/min (AIx75) from baseline to week 24 and 52
no single universally accepted normal range for an AIx@75; lower values indicate better arterial health, with values below 20-25% often considered optimal, and values above 30% associated with increased arterial stiffness and cardiovascular risk
Time frame: from enrollment to the end of treatment at week 52
comparison of change in PWV between the study groups
Time frame: From enrollment to the end of treatment at 52 weeks
change in psoriasis area severity index (PASI)
range 0-72; higher scores mean a worse outcome
Time frame: From enrollment to the end of treatment at 52 weeks
change in ankle-brachial index (ABI)
range 0.9-1.4; higher scores mean worse outcome
Time frame: From enrollment to the end of treatment at 52 weeks
comparison of change in AIx75 between the study groups
Time frame: from enrollment to the end of treatment at 52 weeks
change in body surface area (BSA)
values 0-100%, higher scores mean a worse outcome
Time frame: From enrollment to the end of treatment at 52 weeks
change in physician's global assessment (PGA)
range 0-5; higher scores mean a worse outcome
Time frame: From enrollment to the end of treatment at 52 weeks
change in dermatology life quality index (DLQI)
range 0-30; higher scores mean a worse outcome
Time frame: From enrollment to the end of treatment at 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.